Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this research study is that patients in remission undergoing
myeloablative haploidentical hematopoietic stem cell transplantation (HSCT) on the Thomas
Jefferson University (TJU) 2 Step treatment regimen will have a disease-free survival (DFS)
rate at 1 year that is the same or better than the historical DFS of patients with similar
diagnoses and ages undergoing matched sibling HSCT. Based on a review of the literature a DFS
rate of 50% or better at 1 year would meet the criterion for an effective alternative
therapy. A DFS rate of 75% or better would imply superior efficacy of the TJU 2 Step approach
over T-replete matched sibling HSCT.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University